Results 1 to 10 of about 540,546 (159)

Definition of clinical immunology around the globe [PDF]

Frontiers in Immunology
Immunology has gradually become a core part of many medical specialties. Immune cells and immune mediators are now known to participate in the pathogenesis of a wide variety of diseases and therapies based on the modulation of immune function are ...
José C. Crispín, José C. Crispín, José C. Crispín, Tineke Cantaert, Tineke Cantaert, Alberto Pinzon-Charry, Alberto Pinzon-Charry, Alberto Pinzon-Charry, Domenico Mavilio, Domenico Mavilio, Domenico Mavilio, Ahmed Seri, Ahmed Seri, Pierre Miossec, Pierre Miossec   +14 more
doaj   +2 more sources

Clinical immunology [PDF]

Revista do Instituto de Medicina Tropical de São Paulo, 2005
doaj   +4 more sources

Clinical immunology [PDF]

Postgraduate Medical Journal, 1991
Clinical immunology is a medical specialty with a pathogenetic rather than organ-based focus. The main clinical areas covered are allergic disease, autoimmune disease, lymphoproliferative disease, transplantation and immunodeficiency. The role and training of the physician immunologist and the organ-based specialist with an interest are outlined.
J. Brostoff, G.K. Scadding, D. Male, I.M. Roitt   +3 more
  +7 more sources

What makes TMB an ambivalent biomarker for immunotherapy? A subtle mismatch between the sample-based design of variant callers and real clinical cohort

Frontiers in Immunology, 2023
Tumor mutation burden (TMB) is a widely recognized biomarker for predicting the efficacy of immunotherapy. However, its use still remains highly controversial.
Yuqian Liu, Yuqian Liu, Shenjie Wang, Shenjie Wang, Yixuan Wang, Yifei Li, Xiaoyan Zhu, Xiaoyan Zhu, Xin Lai, Xin Lai, Xuanping Zhang, Xuanping Zhang, Xuqi Li, Xiao Xiao, Xiao Xiao, Jiayin Wang, Jiayin Wang   +16 more
doaj   +1 more source

A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden Threshold

Frontiers in Genetics, 2022
Tumor mutation burden (TMB) is a recognized stratification biomarker for immunotherapy. Nevertheless, the general TMB-high threshold is unstandardized due to severe clinical controversies, with the underlying cause being inconsistency between multiple ...
Yixuan Wang, Xin Lai, Jiayin Wang, Jiayin Wang, Jiayin Wang, Ying Xu, Xuanping Zhang, Xiaoyan Zhu, Yuqian Liu, Yang Shao, Yang Shao, Li Zhang, Wenfeng Fang   +12 more
doaj   +1 more source

Integrated machine learning approaches for flow cytometric quantification of myeloid-derived suppressor cells in acute sepsis

Frontiers in Immunology, 2022
Highly heterogeneous cell populations require multiple flow cytometric markers for appropriate phenotypic characterization. This exponentially increases the complexity of 2D scatter plot analyses and exacerbates human errors due to variations in manual ...
Anthony S. Bonavia, Anthony S. Bonavia, Abigail Samuelsen, Joshua Luthy, E. Scott Halstead   +4 more
doaj   +1 more source

Heterogeneity of magnitude, allergen immunodominance, and cytokine polarization of cockroach allergen‐specific T cell responses in allergic sensitized children

Clinical and Translational Allergy, 2021
Background Characterization of allergic responses to cockroach (CR), a common aeroallergen associated with asthma, has focused mainly on IgE reactivity, but little is known about T cell responses, particularly in children.
Ricardo daSilva Antunes, Aaron Sutherland, April Frazier, Veronique Schulten, Anna Pomés, Jill Glesner, Agustin Calatroni, Matthew C. Altman, Robert A. Wood, George T. O'Connor, Jacqueline A. Pongracic, Gurjit K. Khurana Hershey, Carolyn M. Kercsmar, Rebecca S. Gruchalla, Michelle Gill, Andrew H. Liu, Edward Zoratti, Meyer Kattan, Paula J. Busse, Leonard B. Bacharier, Stephen J. Teach, Lisa M. Wheatley, Alkis Togias, William W. Busse, Daniel J. Jackson, Alessandro Sette   +25 more
doaj   +1 more source

TMBserval: a statistical explainable learning model reveals weighted tumor mutation burden better categorizing therapeutic benefits

Frontiers in Immunology, 2023
A high tumor mutation burden (TMB) is known to drive the response to immune checkpoint inhibitors (ICI) and is associated with favorable prognoses. However, because it is a one-dimensional numerical representation of non-synonymous genetic alterations ...
Yixuan Wang, Jiayin Wang, Wenfeng Fang, Xiao Xiao, Quan Wang, Jian Zhao, Jingjing Liu, Shuanying Yang, Yuqian Liu, Xin Lai, Xiaofeng Song   +10 more
doaj   +1 more source

Evaluation of Subjects Experiencing Allergic Reactions to Non-Steroidal Anti-Inflammatory Drugs: Clinical Characteristics and Drugs Involved

Frontiers in Pharmacology, 2020
Non-steroidal anti-inflammatory drugs (NSAIDs), the most commonly prescribed and consumed medicines worldwide, are the main triggers of drug hypersensitivity reactions (DHRs).
Natalia Pérez-Sánchez, Natalia Pérez-Sánchez, Inmaculada Doña, Gador Bogas, María Salas, Almudena Testera, José A. Cornejo-García, María J. Torres, María J. Torres, María J. Torres, María J. Torres   +10 more
doaj   +1 more source

Ocular Motor Abnormalities in Anti-IgLON5 Disease

Frontiers in Immunology, 2021
ObjectiveAnti-IgLON5 disease forms an interface between neuroinflammation and neurodegeneration and includes clinical phenotypes that are often similar to those of neurodegenerative diseases.
Stefan Macher, Ivan Milenkovic, Tobias Zrzavy, Romana Höftberger, Stefan Seidel, Evelyn Berger-Sieczkowski, Thomas Berger, Paulus S. Rommer, Gerald Wiest   +8 more
doaj   +1 more source